The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis: Follow up of a single-center Italian compassionate use.
Cristina Papayannidis
No relevant relationships to disclose
Simona Soverini
No relevant relationships to disclose
Caterina De Benedittis
No relevant relationships to disclose
Michela Rondoni
No relevant relationships to disclose
Mariachiara Abbenante
No relevant relationships to disclose
Chiara Sartor
No relevant relationships to disclose
Ilaria Iacobucci
No relevant relationships to disclose
Francesca Volpato
No relevant relationships to disclose
Carmen Baldazzi
No relevant relationships to disclose
Emanuela Ottaviani
No relevant relationships to disclose
Anna Ferrari
No relevant relationships to disclose
Viviana Guadagnuolo
No relevant relationships to disclose
Alberto Conficoni
No relevant relationships to disclose
Stefania Paolini
No relevant relationships to disclose
Sarah Parisi
No relevant relationships to disclose
Federica Frabetti
No relevant relationships to disclose
Silvia Piccari
No relevant relationships to disclose
Elisa Lani
No relevant relationships to disclose
Giovanni Martinelli
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer; Roche
Honoraria - Bristol-Myers Squibb; Novartis